The federal judge presiding over the Zoloft multidistrict litigation has approved a discovery plan that the opposing sides negotiated to set relatively early trial dates while also setting early hearings over the science behind the allegations that women’s use of Zoloft during their pregnancies caused birth defects.
The early trial dates are something that favored the plaintiffs counsel’s position while the issue of relatively early Daubert hearings over the scientific evidence is something that favors the defense counsel’s position.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
